
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4425341/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A pilot study on the use of the super dimension navigation system for optimal cryobiopsy location in in in interstitial lung disease diagnostics. Pulmonology, 2023, 29, 119-123.	1.0	8
2	Augmented reality glasses as a new tele-rehabilitation tool for home use: patients' perception and expectations. Disability and Rehabilitation: Assistive Technology, 2022, 17, 480-486.	1.3	15
3	Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nature Reviews Rheumatology, 2022, 18, 85-96.	3.5	28
4	Comorbidities in unclassifiable interstitial lung disease. Respiratory Research, 2022, 23, 59.	1.4	5
5	Effect of a New Tele-Rehabilitation Program versus Standard Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease. Journal of Clinical Medicine, 2022, 11, 11.	1.0	19
6	Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. Human Genomics, 2022, 16, 13.	1.4	3
7	Design and rationale of ProSar, the first Danish sarcoidosis registry Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021044.	0.2	0
8	Fatigue Is a Major Symptom at COVID-19 Hospitalization Follow-Up. Journal of Clinical Medicine, 2022, 11, 2411.	1.0	12
9	Characteristics of Danish Patients with Pulmonary Sarcoidosis. , 2022, , .		0
10	Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs). , 2022, , .		0
11	Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial. , 2022, , .		2
12	A Neo-Epitope Biomarker ofType VI Collagen Formation Reflects Patient-Reported Outcomes. , 2022, , .		0
13	Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Study in Europe. , 2022, , .		0
14	Effect of a Telerehabilitation program in sarcoidosis Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 39, e2022003.	0.2	0
15	Intravenous immunoglobulin treatment stabilizing a patient with Anti-PL7 antisynthetase syndrome with interstitial lung disease and eosinophilic inflammation. Respiratory Medicine Case Reports, 2022, , 101686.	0.2	1
16	Decline in forced vital capacity as a surrogate for mortality in patients with fibrosing interstitial lung diseases*. Pneumologie, 2022, , .	0.1	0
17	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
18	Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment. European Clinical Respiratory Journal, 2021, 8, 1853658.	0.7	6

#	Article	IF	CITATIONS
19	International multidisciplinary team discussions on the diagnosis of idiopathic non-specific interstitial pneumonia and the development of connective tissue disease. European Clinical Respiratory Journal, 2021, 8, 1933878.	0.7	1
20	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology, 2021, 60, 5601-5609.	0.9	10
21	The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal, 2021, 57, 2100079.	3.1	10
22	Integration of cryobiopsies for interstitial lung disease diagnosis is a valid and safe diagnostic strategy—experiences based on 250 biopsy procedures. Journal of Thoracic Disease, 2021, 13, 1455-1465.	0.6	12
23	Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study. Journal of Clinical Medicine, 2021, 10, 1078.	1.0	10
24	High turnover of types <scp>III</scp> and <scp>VI</scp> collagen in progressive idiopathic pulmonary fibrosis. Respirology, 2021, 26, 582-589.	1.3	7
25	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	1.4	22
26	A Pilot Study on the Utility of SuperDimension to Guide Cryobiopsies in ILDs. , 2021, , .		0
27	Fibrin Formation Measured in Serum Is Related to Disease Severity in IPF Patients. , 2021, , .		0
28	Decline in Forced Vital Capacity as a Surrogate for Mortality in Patients with Fibrosing Interstitial Lung Diseases. , 2021, , .		1
29	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
30	Estimated Global Prevalence of Idiopathic Pulmonary Fibrosis. , 2021, , .		0
31	Health Related Quality of Life and Symptoms Are Related to Mortality in Idiopathic Pulmonary Fibrosis. , 2021, , .		0
32	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6
33	Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 205.	1.4	20
34	Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a realâ€world multicentre cohort. Respirology, 2021, 26, 982-988.	1.3	13
35	Global incidence and prevalence of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 197.	1.4	170
36	Clusters of comorbidities in idiopathic pulmonary fibrosis. Respiratory Medicine, 2021, 185, 106490.	1.3	13

#	Article	IF	CITATIONS
37	Tele-Rehabilitation Program in Idiopathic Pulmonary Fibrosis—A Single-Center Randomized Trial. International Journal of Environmental Research and Public Health, 2021, 18, 10016.	1.2	27
38	Comparison of Palliative Care Models in Idiopathic Pulmonary Fibrosis. Applied Sciences (Switzerland), 2021, 11, 9028.	1.3	2
39	Screening Tools for Depression and Anxiety in Patients with Chronic Obstructive Pulmonary Disease – A Systematic Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 683-689.	0.7	8
40	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	1.2	8
41	Interstitial lung diseases: quo vadis?. Lancet Respiratory Medicine,the, 2021, 9, 1084-1087.	5.2	4
42	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
43	An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettes. European Clinical Respiratory Journal, 2021, 8, 1861580.	0.7	7
44	Validation of a derived version of the IPF-specific Saint George's Respiratory Questionnaire. Respiratory Research, 2021, 22, 259.	1.4	2
45	P-101â€Occupational dust exposures and CT findings of interstitial lung disease and chronic obstructive pulmonary disease. , 2021, , .		0
46	Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort. Journal of Clinical Medicine, 2021, 10, 4830.	1.0	14
47	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 382.	0.8	5
48	PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 5562.	1.0	13
49	Pulmonary Alveolar Microlithiasis - A Review Yale Journal of Biology and Medicine, 2021, 94, 637-644.	0.2	1
50	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration, 2020, 99, 73-82.	1.2	58
51	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	2.5	171
52	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	3.0	82
53	Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease. European Clinical Respiratory Journal, 2020, 7, 1840706.	0.7	5
54	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508

#	Article	IF	CITATIONS
55	The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	1.4	33
56	Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease – a randomised placebo-controlled trial. Respiratory Research, 2020, 21, 195.	1.4	22
57	Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Multiple Comorbidities. , 2020, , .		Ο
58	Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics. Drug Safety, 2020, 43, 953-955.	1.4	1
59	Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. European Clinical Respiratory Journal, 2020, 7, 1807682.	0.7	7
60	Inhaled GM-CSF (Molgramostim) Therapy Reduces the Need for Whole Lung Lavage in Patients with Autoimmune Pulmonary Alveolar Proteinosis - Long-Term Results from a Randomized, Double-Blind Trial (IMPALA). , 2020, , .		0
61	Eight novel variants in the <i>SLC34A2</i> gene in pulmonary alveolar microlithiasis. European Respiratory Journal, 2020, 55, 1900806.	3.1	14
62	Advance care planning and longer survival in the terminally ill: a randomised controlled trial unexpected finding. BMJ Supportive and Palliative Care, 2020, 10, 221-222.	0.8	8
63	Early referral to palliative care in IPF – pitfalls and opportunities in clinical trials. Respiratory Research, 2020, 21, 174.	1.4	2
64	Desquamative interstitial pneumonia: a systematic review of its features and outcomes. European Respiratory Review, 2020, 29, 190181.	3.0	32
65	Attitude and Barriers in Palliative Care and Advance Care Planning in Nonmalignant Chronic Lung Disease: Results From a Danish National Survey. Journal of Palliative Care, 2020, 35, 232-235.	0.4	12
66	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
67	Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 91.	1.4	21
68	Managing the supportive care needs of those affected by COVID-19. European Respiratory Journal, 2020, 55, 2000815.	3.1	95
69	Pulmonary alveolar microlithiasis: no longer in the stone age. ERJ Open Research, 2020, 6, 00289-2020.	1.1	12
70	Efficacy and safety of nintedanib in the elderly patient with IPF*. , 2020, 74, .		0
71	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
72	Tele-delivered mindfulness-based cognitive therapy in chronic obstructive pulmonary disease: A mixed-methods feasibility study. Journal of Telemedicine and Telecare, 2019, 25, 468-475.	1.4	13

ELISABETH BENDSTRUP

#	Article	IF	CITATIONS
73	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 2019, 35, 2015-2024.	0.9	148
74	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60
75	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality. Respiration, 2019, 98, 455-460.	1.2	47
76	Surgical Lung Biopsy and Cryobiopsy in Fibrosing Interstitial Lung Diseases: One Swallow Does Not Make a Summer. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 939-940.	2.5	4
77	Validation of the IPF-specific version of St. George's Respiratory Questionnaire. Respiratory Research, 2019, 20, 199.	1.4	37
78	Differences in the Approach to Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE IPF) Between Expert Centres and General Pulmonologists: Results from an International Survey. , 2019, , .		0
79	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	1.3	15
80	Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 103.	1.4	78
81	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
82	Advance care planning for patients with lung, heart and cancer diseases and their relatives. International Journal of Palliative Nursing, 2019, 25, 112-127.	0.2	12
83	Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study. European Clinical Respiratory Journal, 2019, 6, 1583516.	0.7	19
84	Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Annals of the American Thoracic Society, 2019, 16, 927-930.	1.5	16
85	Report Standardization in Transbronchial Lung Cryobiopsy. Archives of Pathology and Laboratory Medicine, 2019, 143, 416-417.	1.2	10
86	Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians. Journal of Clinical Medicine, 2019, 8, 2038.	1.0	51
87	Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2019, 19, 255.	0.8	22
88	Pulmonary alveolar proteinosis - a crazy presentation of dyspnea. European Clinical Respiratory Journal, 2019, 6, 1552065.	0.7	0
89	Tracheal collapsibility in adults is dynamic over time. Respiratory Medicine, 2019, 146, 124-128.	1.3	4
90	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration, 2019, 97, 173-184.	1.2	39

#	Article	IF	CITATIONS
91	Efficacy and safety of nintedanib in the elderly patient with IPF. , 2019, , .		1
92	Ein globaler Blick auf akute Exazerbationen der idiopathischen Lungenfibrose (AE-IPF): Ergebnisse einer internationalen Umfrage. , 2019, 73, .		0
93	New-onset asthma in a bilateral lung transplant patient. BMJ Case Reports, 2019, 12, e231654.	0.2	1
94	Childhood pneumothorax in Birtâ€Hoggâ€Dubé syndrome: A cohort study and review of the literature. Molecular Genetics & Genomic Medicine, 2018, 6, 332-338.	0.6	15
95	Mindfulness-based cognitive therapy in COPD: a cluster randomised controlledÂtrial. European Respiratory Journal, 2018, 51, 1702082.	3.1	52
96	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	1.2	42
97	COPD: an overlooked cause of excess mortality in patients with rheumatoid arthritis. Lancet Respiratory Medicine,the, 2018, 6, 326-327.	5.2	12
98	Coâ€morbidity and mortality among patients with interstitial lung diseases: A populationâ€based study. Respirology, 2018, 23, 606-612.	1.3	13
99	Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim). Respiratory Medicine Case Reports, 2018, 23, 167-169.	0.2	4
100	Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. European Clinical Respiratory Journal, 2018, 5, 1530029.	0.7	13
101	Economic consequences of idiopathic pulmonary fibrosis in Denmark. ERJ Open Research, 2018, 4, 00045-2017.	1.1	4
102	Cryobiopsies are diagnostic in Pleuroparenchymal and Airway-centered Fibroelastosis. Respiratory Research, 2018, 19, 135.	1.4	11
103	Familial idiopathic pulmonary fibrosis in a young female. Respiratory Medicine Case Reports, 2018, 24, 1-4.	0.2	4
104	Increased mortality among patients with rheumatoid arthritis and COPD: A population-based study. Respiratory Medicine, 2018, 140, 101-107.	1.3	22
105	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. , 2018, , .		5
106	Introduction of cryobiopsies in the diagnostics of interstitial lung diseases – experiences in a referral center. European Clinical Respiratory Journal, 2017, 4, 1274099.	0.7	44
107	Preferred Place of Care and Death in Terminally Ill Patients with Lung and Heart Disease Compared to Cancer Patients. Journal of Palliative Medicine, 2017, 20, 1217-1224.	0.6	54
108	A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Annals of the Rheumatic Diseases, 2017, 76, 1700-1706.	0.5	263

#	Article	IF	CITATIONS
109	Birt–Hogg–Dubé syndrome: a case report and a review of the literature. European Clinical Respiratory Journal, 2017, 4, 1292378.	0.7	24
110	A systematic review of occupational exposure to coal dust and the risk of interstitial lung diseases. European Clinical Respiratory Journal, 2017, 4, 1264711.	0.7	35
111	Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome. Respiratory Medicine Case Reports, 2017, 22, 263-265.	0.2	13
112	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
113	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
114	Hypersensitivity pneumonitis among wind musicians – an overlooked disease?. European Clinical Respiratory Journal, 2017, 4, 1351268.	0.7	9
115	Voriconazole Concentrations in Plasma and Epithelial Lining Fluid after Inhalation and Oral Treatment. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 430-434.	1.2	19
116	FRI0174â€A population based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. , 2017, , .		0
117	Lung ultrasound has limited diagnostic value in rare cystic lung diseases: a cross-sectional study. European Clinical Respiratory Journal, 2017, 4, 1330111.	0.7	12
118	Screening tools for evaluation of depression in Chronic Obstructive Pulmonary Disease (COPD). A systematic review. European Clinical Respiratory Journal, 2017, 4, 1332931.	0.7	19
119	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	2.7	27
120	Unclassifiable interstitial lung diseases: Clinical characteristics and survival. Respirology, 2017, 22, 494-500.	1.3	58
121	0435â€Pigeon breeding and the risk of interstitial lung disease, does number of pigeons matter?. , 2017, , .		0
122	Tracheal collapse diagnosed by multidetector computed tomography: evaluation of different image analysis methods. European Clinical Respiratory Journal, 2017, 4, 1407624.	0.7	4
123	Lung Ultrasound $\hat{a} \in A$ Novel Diagnostic Tool To Phenotype Chronic Lung Allograft Dysfunction?. Ultrasound International Open, 2017, 03, E117-E119.	0.3	5
124	Erectile dysfunction is a common problem in interstitial lung diseases. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 356-364.	0.2	2
125	Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 2-17.	0.2	15
126	Careful Planning Reduces Cryobiopsy Complications. Annals of the American Thoracic Society, 2017, 14, 1229.	1.5	2

#	Article	IF	CITATIONS
127	NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease. European Clinical Respiratory Journal, 2016, 3, 32027.	0.7	13
128	O40-1â€Risk of hypersensitivity pneumonitis and other interstitial lung diseases among pigeon breeders. , 2016, , .		0
129	Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. European Clinical Respiratory Journal, 2016, 3, 32608.	0.7	26
130	Opioids: an unexplored option for treatment of dyspnea in IPF. European Clinical Respiratory Journal, 2016, 3, 30629.	0.7	48
131	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	5.2	337
132	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	5.2	108
133	Risk of hypersensitivity pneumonitis and interstitial lung diseases among pigeon breeders. European Respiratory Journal, 2016, 48, 818-825.	3.1	20
134	Eosinophil alveolitis in two patients with idiopathic pulmonary fibrosis. Respiratory Medicine Case Reports, 2016, 19, 61-64.	0.2	6
135	Immunoglobulin G4-related pleuritis – A case report. Respiratory Medicine Case Reports, 2016, 19, 18-20.	0.2	16
136	Pulmonary hemorrhage following anabolic agent abuse: Two cases. Respiratory Medicine Case Reports, 2016, 18, 45-47.	0.2	2
137	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, e56.	0.4	13
138	Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. European Clinical Respiratory Journal, 2015, 2, 28348.	0.7	9
139	Rituximab-induced interstitial lung disease: five case reports. European Clinical Respiratory Journal, 2015, 2, 27178.	0.7	21
140	Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respiratory Medicine, 2015, 109, 443-450.	1.3	26
141	Emphysema mimicking interstitial lung disease: Two case reports. Respiratory Medicine Case Reports, 2015, 15, 24-26.	0.2	3
142	Granulomatous-lymphocytic interstitial lung disease and recurrent sinopulmonary infections in a patient with Good's syndrome. BMJ Case Reports, 2015, 2015, bcr2014205635.	0.2	9
143	Challenges in the classification of fibrotic ILD. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 4-9.	0.2	2
144	How does comorbidity influence survival in idiopathic pulmonary fibrosis?. Respiratory Medicine, 2014, 108, 647-653.	1.3	125

#	Article	IF	CITATIONS
145	A cohort study of interstitial lung diseases in central Denmark. Respiratory Medicine, 2014, 108, 793-799.	1.3	128
146	No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis. Respiratory Medicine Case Reports, 2014, 12, 47-49.	0.2	2
147	0191â€Are indoor concentrations of airborne mould spores in non-industrial environments sufficiently high to cause hypersensitivity pneumonitis?. Occupational and Environmental Medicine, 2014, 71, A85.2-A85.	1.3	Ο
148	Autoimmune pulmonary alveolar proteinosis: Treatment options in year 2013. Respirology, 2013, 18, 82-91.	1.3	58
149	Increasing awareness of corticosteroid hypersensitivity reactions is important. Respirology Case Reports, 2013, 1, 43-45.	0.3	4
150	Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2013, 30, 249-61.	0.2	12
151	Pulmonary alveolar microlithiasis: two case reports and review of the literature. European Respiratory Review, 2012, 21, 249-256.	3.0	45
152	SLC34A2 Gene Mutation May Explain Comorbidity of Pulmonary Alveolar Microlithiasis and Aortic Valve Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 464-464.	2.5	21